Last updated on December 2018

Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC

Brief description of study

This is a Phase 3, randomized, open-label, multicenter, global study designed to compare the efficacy and safety of BGB-A317 versus sorafenib as a first-line systemic treatment in patients with unresectable hepatocellular carcinoma. This study also includes a substudy investigating the safety, tolerability, PK, and preliminary efficacy in HCC in Japanese patients. In Japan, preliminary safety and tolerability will be evaluated (Safety Run-In Substudy) before Japanese patients are recruited in this Phase 3 study.

Clinical Study Identifier: NCT03412773

Find a site near you

Start Over

St. Jude Heritage Healthcare

Fullerton, CA United States
  Connect »

Ingalls Memorial Hospital

Harvey, IL United States
  Connect »

The Mays Cancer Center

San Antonio, TX United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.